Overview

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Status:
Withdrawn

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and establish the maximum tolerated dose (MTD) of omacetaxine in combination with azacitidine and G-CSF in patients with relapsed and/or refractory MDS.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Florida

Collaborator:

Teva Pharmaceutical Industries, Ltd.

Treatments:

Azacitidine
Homoharringtonine
Lenograstim